Retina Synthesis

Retina Synthesis episodes:

• 05.31.2024

  The Davio 2 Trial for Neovascular AMD

  We review the 6 month results of the Davio 2 trial of the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.

  
• 05.17.2024

  The GALE Extension Study

  We discuss the latest promising results from the GALE extension study of pegcetacoplan with Dr. Ashkan Abbey of Texas Retina Associates

  
• 05.09.2024

  AXPAXLI for Diabetic Retinopathy

  We discuss the promising phase I results of the Helios trial studying AXPAXLI TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.

  
• 04.18.2024

  NSAIDS in the treatment of Central Serous Chorioretinopathy

  We discuss the use of non steroidal inflammatory agents in the management of central serous chorioretinopathy with Dr. Michael Singer of San Antonio, Texas

  
• 04.04.2024

  EY-103 a novel Wnt Pathway Agonist for Treatment of DME and neovascular AMD

  We discuss remarkable preliminary results from the the use of intravitreal EYE-103, a novel Wnt pathway agonist in the treatment of DME and neovascular AMD with Dr. Charles Wykoff of Houston Texas.

  
• 03.28.2024

  Intravitreal Gene Therapy for neovascular AMD with 4D-150

  We discuss the first interim results of a novel intravitreal gene therapy agent, 4D-150, with Dr. Arshad Khanani of Sierra Eye Associates and the University of Nevada Reno School of Medicine.

  
• 03.21.2024

  KSI 501 Bispecific Anti-VEGF Biopolymer Treatment of DME

  We discuss the use of a novel bispecific anti-VEGF Anti IL-6 Antibody Biopolymar Conjugate for the treatment of DME with Dr. Mark R. Barakat of Phoenix, AZ.

  
• 03.14.2024

  Retinal Vasculitis Following Pegcetcoplan Therapy of Geographic Atrophy

  We discuss the occurrence of retinal vasculitis following pegcetcoplan therapy of geographic atrophy with Dr. Andrew Witkin of the New England Eye Center, Tufts University School of Medicine

  
• 03.07.2024

  High Dose Aflibercept in Severe Diabetic Macular Edema

  We discuss the treatment results of high dose aflibercept in the eyes in the most severe quartile of diabetic macular edema with Dr. Roger Goldberg of Walnut Creek, California.

  
• 02.29.2024

  IL-6 Inhibition in the Treatment of Uveitis Macular Edema

  We discuss the use of an IL-6 inhibitor in the treatment of uveitis macular edema with Dr. Sumit Sharma of the Cole Eye Institute, Cleveland Clinic.

  
• 02.22.2024

  The High Dose Aflibercept DME Trial

  We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.

  
• 02.15.2024

  The Annexon Geographic Atrophy Trial

  We discuss the unique results of the Annexon geographic atrophy Phase I clinical trial with Dr. Roger Goldberg of Bay Area Retina Associates, Walnut Creek, California

  
• 02.08.2024

  Diagnostics for Retinoblastoma

  We review the latest diagnostic and therapeutic approaches for retinoblastoma with Dr. Jesse Berry, Associate Professor of Ophthalmology, Children's Hospital Los Angeles.

  
• 02.01.2024

  A Feasbility Evaluating the Use of Home OCT for a Clinical Trial of Faricimab Treatment of nAMD

  We discuss the feasibility of using home OCT vs. a treat and extend approach in a clinical trial of faricimab in neovascular AMD with Dr. Kevin Blinder of the Retina Institute in Saint Louis, Mo and Profesor of Ophthalmology at...

  
• 01.25.2024

  Visual Outcomes in the Davio Trial Looking at TKI EY-1901

  We discuss the characteristics of eyes with the best visual outcomes in the Davio trial of TKI EY-1901 with Dr. Philip Storey of the Austin Retina Associates, Austin, Texas.

  
• 01.18.2024

  A Post-Hoc Comparison of Syfovre and Izervay in Treatment of Geographic Atrophy

  We discuss a post-hoc study comparing the efficacy of Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) with Paul Hahn, MD, PhD, of NJ Retina.

  
• 01.11.2024

  4 Year Results from DRCR Network Protocol W

  We discuss a comparative trial of preventive therapy for non-proliferative retinopathy vs. ad hoc treatment of disease complications with Dr. Hani Salehi-Had of Retina Associates of Southern California, Huntington Beach, California.

  
• 01.04.2024

  Gene Therapy for X-Linked Retinitis Pigmentosa

  We discuss the latest information on phase 2 trials of gene therapy for x-linked retinitis pigmentosa with Dr. Nadia Waheed, Chief Medical Officer of Beacon Therapeutics and Associate Professor of Ophthalmology at the New England Eye Center, Tufts University School...

  
• 12.21.2023

  Optogenetic Therapy of Inherited Retinal Degenerations

  We discuss the use of optogenetics for the treatment of inherited retinal degenerations with Dr. Jose Sahel, Chairman and Distinguished Professor of Ophthalmology at the University of Pittsburgh School of Medicine.

  
• 12.14.2023

  A Real World Analysis of Aflibercept Therapy of Diabetic Macular Edema

  We discuss the importance of intensive therapy of DME, when using aflibercept for DME, as suggested by a review of real world cases from the Vestrum data base, with Dr. Ferhina Ali, Assistant Professor of Ophthalmology, New York Medical...

  
• 12.07.2023

  Topical Therapy of Diabetic Macular Edema

  We discuss the use of a topical agent for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Research, Sierra Eye Associates, Associate Clinical Professor of Ophthalmology, University Nevada School of Medicine, Reno.

  
• 11.30.2023

  Mitochrondial Therapy of Intermediate AMD

  We review novel approaches for the treatment of intermediate AMD, with Dr. Barry Kuppermann, Director Gavin Herbert Eye Institute, Chairman Department of Ophthalmology, University of California Irvine, Steinert Endowed Chair.

  
• 11.16.2023

  Safety Considerations in Retinal Gene Therapy

  In our latest update, we discuss safety issues associated with retinal gene therapy with Professor Glenn Yiu of the University of California School of Medicine.

  
• 11.09.2023

  An Oral Agent for Treatment of Diabetic Retinopathy

  We discuss the use of a novel oral agent for the treatment of diabetic retinopathy with David R. Lally, MD, Director of Research, New England Retina Consultants, Springfield, MA

  
• 10.26.2023

  Intravitreal Gene Therapy with 4D-150

  We discuss intravitreal gene therapy with a new agent, 4D-150 with Veeral Sheth, MD, MBA Assistant Clinical Professor of Ophthalmology University of Illinois at Chicago.

  
• 10.19.2023

  Optogenetics in the Treatment of Retinal Degenerations

  We discuss the use of optogenetics in the treatment of retinal degenerations with Dr. Michael Singer, Adjunct Professor of Ophthalmology, University of Texas Health Science Center, San Antonio.

  
• 10.12.2023

  Update on the Iluvien System for Treatment of Diabetic Macular Edema

  We discuss retinal drying in diabetic macular edema using the Iluvien implant with Dr. Michael Singer, Adjunct Professor, University of Texas Health Science Center, San Antonio.

  
• 10.05.2023

  The Ophthea Clinical Trial for Neovascular AMD

  We discuss the use of blockade of VEGF C and D in the treatment of neovascular AMD with Dr. Dante Pieramici, California Retina Research Foundation, California Retina Consultants.

  
• 09.28.2023

  Senolytic Therapy for Diabetic Macular Edema

  We discuss the use of a novel treatment approach, senolytic therapy, for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Professor, USC Roski Eye Institute.

  
• 09.21.2023

  The Port Delivery System for Treating Diabetic Retinopathy

  We discuss the use of the PDS in the treatment of diabetic retinopathy and diabetic macular edema with Professor Carl Regillo of the Wills Eye Hospital.

  
• 09.14.2023

  A Profile of Eugene de Juan, MD

  Dr. Eugene de Juan, winner of this year's ASRS Pyron Award, joins us to discuss his career highlights. Dr. de Juan is CEO of Forsight Labs and Professor of Ophthalmology, University of California, San Francisco.

  
• 09.07.2023

  Subretinal Gene Therapy for Neovascular AMD

  In our latest update, We discuss the use of surgical sub retinal gene therapy for neovascular AMD with RGX-314. Our guest Dr. Courtney Crawford, Ft. Worth, Texas.

  
• 08.31.2023

  An Implantation Telescope for Macular Disease

  We discuss the use of an improved implantable telescope as a low vision aid in patients with macular disease with Dr. David Almeida, Erie Retina Research.

  
• 08.24.2023

  Prevention of Vision Loss in the Gather Trial of IZERVAY

  We discuss the prevention of vision loss in the Gather 2 trial of IZERVAY with Dr. Carl Danzig of the Rand Eye Institute, Pompano Beach, Florida

  
• 08.14.2023

  GALE Long Term Extension Study for GA

  We discuss a 30-Month Outcome with Pegcetacoplan for the Treatment of Geographic Atrophy with Nathan Steinle MD, California Retina Consultants, Santa Barbara, California.

  
• 08.11.2023

  Pegcetacoplan (SYFOVRE) Clinical Update

  We discuss the latest information on Safety & Efficacy in Clinic and Clinical Trials with Cedric Francois, MD, PhD.

  
• 08.03.2023

  Faricimab in Neovascular AMD

  We discuss the latest information on the use of faricimab in neovascular AMD with Dr. Yasha Modi, Associate Professor of Ophthalmology, NYU Langone Medical Center.

  
• 07.27.2023

  High Dose Aflibercept for Neovascular AMD

  We discuss the use of high dose aflibercept for the treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor, Roski Eye Institute of USC.

  
• 07.20.2023

  Pegcetacoplan for Geographic Atrophy Update

  We discuss the latest information on the use of pegcetacoplan for geographic atrophy in AMD with Dr. Dilsher Dhoot, California Retinal Consultants.

  
• 07.13.2023

  Ocular Therapeutix: A TKI and Hydrogel Implant

  We discuss the use of a novel drug (tyrosine kinase inhibitor) and novel delivery system (hydrogel) for the treatment of neovascular AMD with Dr. Peter Kaiser of the Cleveland Clinic.

  
• 07.06.2023

  Biosimilar Drugs for Retinal Diseases

  We discuss the use of biosimilar drugs for retinal diseases with Dr. Arghavan Almony, author of definitive monograph of these agents.

  
• 06.29.2023

  Faricimab vs Aflibercept in Diabetic Macular Edema

  In our latest update, we discuss the relative drying effects of faricimab and aflibercept in the treatment of diabetic macular edema with Dr. Roger Goldberg.

  
• 06.22.2023

  Artificial Intelligence in the Management of Geographic Atrophy

  In our latest update, we discuss the use of artificial intelligence in the management of geographic atrophy with Professor Pearse Keane, Moorfields Eye Hospital, London.

  
• 06.15.2023

  Molecular Diagnostics in the Diagnosis and Treatment of Uveal Melanoma

  In our latest update, we discuss the use of molecular techniques in the management of uveal melanoma with Dr. William Harbour, Professor and Chair, Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.

  
• 06.08.2023

  Faricimab in the Treatment of Retinal Venous Occlusion

  We discuss the results of clinical trials studying the use of faricimab in the treatment of retinal venous occlusion with Dr. Ramin Tadayoni, Professor of Ophthalmology University of Paris.

  
• 06.01.2023

  The Use of High Dose Aflibercept in Diabetic Macular Edema

  We review the one year results of a clinical trial using high dose aflibercept (8mg) for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Clinical Professor of Ophthalmology, USC Roski Eye Institute

  
• 05.25.2023

  Widefield OCT Angiography

  We the discuss the use of wide field OCT angiography in the management of diabetic retinopathy, retinal vein occlusion, and pediatric retinal disease with Dr. Amir Kashani, Associate Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins School of Medicine

  
• 05.18.2023

  Aflibercept Therapy of Retinopathy of Prematurity

  We review the use of anti-VEGF therapy for retinopathy of prematurity and in particular, the results of a clinical trial employing aflibercept with Dr. Darius Moshfeghi, Professor of Ophthalmology, Director of the Retina Service, Byers Eye Institute, Stanford University School...

  
• 05.11.2023

  Home OCT in the Management of Neovascular AMD: Latest Development

  We discuss the use of home OCT and artificial intelligence in the management of anti-VEGF therapy of neovascular AMD with Dr. Anat Loewenstein, Director, Department of Ophthalmology, Tel Aviv Medical Center, Israel.

  
• 05.04.2023

  Suprachoroidal Corticosteroids for the Treatment of Macular Edema

  We discuss the use of suprachoroidal triamcinolone for the treatment of macular edema with Dr. Steven Yeh, Truhlsen Chair of Ophthalmology, University of Nebraska School of Medicine.